MediPharm Labs Completes First Shipment to France

Core Insights - MediPharm Labs Corp. has completed its first shipment of pharmaceutical-grade cannabis products to France, marking its entry into the European medical cannabis market [1][2] - The French medicinal cannabis market is projected to grow from US$187.6 million in 2025 to US$213.3 million by 2030, indicating significant potential for the company [2] - As of Q3 2025, international medical cannabis accounted for 56% of MediPharm's total revenue, with an 83% year-over-year growth in this segment [2] Company Overview - Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products [4] - The company operates a Good Manufacturing Practices certified facility and has invested in advanced technology and research-driven teams to ensure high-quality product delivery [4] - MediPharm Labs holds a Pharmaceutical Drug Establishment License from Health Canada, making it the only North American company with a commercial-scale domestic GMP License for cannabinoid extraction [5] Strategic Partnerships and Expansion - The recent shipment to France follows a production agreement with an international medicinal cannabis organization, enhancing MediPharm's reputation as a trusted supplier [2] - The company has established distribution and supply partnerships globally, now shipping products to 10 countries [3] - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany [6]